Close

Flexion Therapeutics (FLXN) Clinical Hold Resolution Could Come Sooner than Expected, Summer Street Says

November 26, 2014 10:37 AM EST Send to a Friend
Summer Street analyst Jim Molloy reiterated a Buy rating and $28 price target on Flexion Therapeutics (NASDAQ: FLXN) Wednesday, saying ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login